Subjects with inactive central nervous system (CNS) metastasis are eligible..
Active, untreated central nervous system (CNS) metastasis
Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis
Symptomatic central nervous system (CNS) malignancy or metastasis.
Have symptomatic central nervous system malignancy or metastasis.
Have symptomatic central nervous system (CNS) malignancy or metastasis.
Symptomatic central nervous system metastasis (e.g., patients requiring increasing doses of steroids)
Have symptomatic central nervous system (CNS) malignancy (with the exception of medulloblastoma) or metastasis (screening not required).
Central nervous system (CNS) metastasis.
Patients with active (untreated or relapsed) central nervous system (CNS) metastasis of the patients myeloma
Central nervous system (CNS) metastasis
About to undergo palliative radiation for a symptomatic central nervous system (CNS) metastasis
Central nervous system (CNS) metastasis
Active (symptomatic) central nervous system (CNS) metastasis.
Presence of untreated and/or symptomatic central nervous system (CNS) metastasis
History of asymptomatic or symptomatic central nervous system (CNS) metastasis
Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis
History of central nervous system (CNS) metastasis.
Patients with active (untreated or relapsed) central nervous system (CNS) metastasis of the patients myeloma
Symptomatic central nervous system (CNS) metastasis.
Symptomatic brain metastasis or uncontrolled central nervous system (CNS) metastasis will not be permitted
Has active central nervous system (CNS) or leptomeningeal metastasis
Have symptomatic central nervous system metastasis. Screening of asymptomatic participants is not required for enrollment.
Central nervous system (CNS) metastasis.
Have the presence of unstable central nervous system (CNS) metastasis.
Have symptomatic central nervous system (CNS) malignancy or metastasis (screening not required).
Active or untreated central nervous system (CNS) metastasis
Have clinical evidence or a history of central nervous system (CNS) metastasis
Known untreated central nervous system (CNS) metastasis
Symptomatic Central Nervous System (CNS) metastasis
Central nervous system (CNS) metastasis
Have symptomatic central nervous system (CNS) malignancy or metastasis. Screening of asymptomatic subjects without history of CNS metastases is not required.
Symptomatic central nervous system (CNS) malignancy or metastasis.
Patients with active (untreated or relapsed) central nervous system (CNS) metastasis of the patients myeloma
History of central nervous system (CNS) metastasis that are untreated or not stable
Clinically unstable central nervous system (CNS) metastasis
Clinical evidence of central nervous system (CNS) metastasis.
For Dose Escalation (Part A): Have central nervous system (CNS) malignancy or metastasis
Have active central nervous system (CNS) metastasis
Symptomatic central nervous system disease, malignancy, or metastasis
Known untreated central nervous system (CNS) metastasis
Known central nervous system (CNS) disease except for treated brain metastasis
Evidence of central nervous system (CNS) metastasis who have not received prior definitive therapy for their lesions.
Current uncontrolled central nervous system (CNS) metastasis or malignant brain tumors
Patients with Central Nervous System (CNS) metastasis which are: symptomatic or require treatment for symptom control and/or growing
Symptomatic central nervous system malignancy or metastasis (screening not required).
Have symptomatic central nervous system (CNS) malignancy or metastasis
Active untreated central nervous system (CNS) metastasis
Known untreated central nervous system (CNS) metastasis; patients with CNS metastasis will be allowed on study once treated
Known brain metastasis or primary central nervous system (CNS) malignancy
Patient must not have untreated or symptomatic central nervous system (CNS) metastasis
Have symptomatic central nervous system (CNS) malignancy or metastasis.
Subjects with symptomatic brain metastasis or central nervous system (CNS) disease
